Understanding how metabolic changes affect the immune response in metastatic breast cancer
Official title: Determining the Impact of Metabolic Adaptations on the Immune-Tumor Microenvironment in Metastatic Breast Cancer
Funded at Roswell Park Cancer Institute Corp · NIH-11058584 · Data updated 2026-11-12
This study is looking at how certain cancer cells in triple-negative breast cancer adapt to survive and avoid being attacked by the immune system, focusing on a specific enzyme called PFKFB4, to find new ways to boost treatment and help patients fight their cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $719,799 |
| NIH project number | 1R01CA285707-01A1 |
| Project ID | NIH-11058584 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple-negative breast cancer, particularly those with metastatic disease.
✕Less likely to help
Patients with non-metastatic breast cancer or other types of cancer may not benefit from this research.
What this research studies
This research investigates the tumor microenvironment in triple-negative breast cancer (TNBC) and how tumor cells adapt to limited nutrients and evade immune detection. It focuses on a specific enzyme, PFKFB4, which may drive aggressive cancer behavior and influence patient outcomes. By studying the effects of PFKFB4 on tumor growth and immune response, the research aims to identify new therapeutic targets that could enhance anti-tumor immunity and improve treatment responses. The approach includes advanced imaging techniques and genetic analysis to understand the relationship between metabolism and immune function in tumors.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the immune system's ability to fight metastatic breast cancer.
How similar studies have gone: Other research has shown promising results in targeting metabolic pathways to improve cancer treatment outcomes, suggesting this approach may be effective.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Dasgupta, Subhamoy — Roswell Park Cancer Institute Corp
- Study coordinator: Dasgupta, Subhamoy
Related research
Other NIH-funded projects on the same topics.
-
Understanding FGFR1-amplified breast cancer to overcome endocrine resistance
This project explores why a type of breast cancer with FGFR1 changes stops responding to hormone therapy and looks for new combination treatments that may help patients live longer.
-
Oral fulvestrant as the next standard of care for ER+ metastatic breast cancer
A new oral formulation of fulvestrant is being tested to help people with ER-positive metastatic breast cancer have a longer, better-tolerated response to treatment.
-
Fit2ThriveMB: A digital activity program to help people with metastatic breast cancer feel better and stay active
A digital, at-home physical activity program designed for people with metastatic breast cancer to improve quality of life and daily functioning.
-
Acupuncture to ease symptoms for people with metastatic breast cancer
A clinical trial will test whether weekly acupuncture for 12 weeks can reduce symptom burden for people with metastatic breast cancer who are on standard therapy.
-
Predicting end-of-life timing to guide better care for metastatic breast cancer
A clinician-facing project tests a breast cancer prognostic tool in everyday oncology care to help guide conversations and timely hospice referrals for patients nearing the end of life.
-
Combining antibody-drug conjugates with mechanism-based therapies to treat metastatic triple-negative breast cancer
A research team is testing new combination strategies that pair antibody-drug conjugates with other targeted treatments to better treat metastatic triple-negative breast cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.